Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab ± Carfilzomib vs Standard-of-Care in Relapsed/Refractory Multiple Myeloma
2024-519504-27-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab in multiple myeloma (MM) (3 arms), sponsored by Regeneron Pharmaceuticals. Planned start Feb 2026; status: authorised.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-519504-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519504-27-00.